A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

Iwahori Yuki0 个研究点目标入组 654 人开始时间: 2023年6月29日最近更新: 2023年10月17日

试验速览

阶段: 3 期
状态: 招募中
发起方
入组人数: 654

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•Able to understand and give written informed consent.
•Must have adequate tumor tissue sample from locally recurrent or metastatic site.
•Documented evidence of HR+ metastatic breast cancer (mBC) confirmed with the most recently available tumor biopsy from a locally recurrent or metastatic site.
•Documented evidence of HER2- status.
•Documented PD by computed tomography (CT) or magnetic resonance imaging during or after the most recent therapy per RECIST v1.1 criteria.
•Candidate for the first chemotherapy in the locally advanced or metastatic setting.
•Eligible for capecitabine, nab-paclitaxel, or paclitaxel.
•Individuals must have one of the following:
•- Disease progression on at least 2 or more previous lines of endocrine therapy (ET) with or without a targeted therapy in the metastatic setting.
•->Disease recurrence while on the first 24 months of starting adjuvant ET will be considered a line of therapy; these individuals will only require 1 line of ET in the metastatic setting.
•- Disease progression within 6 months of starting first-line ET with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting.
•- Disease recurrence while on the first 24 months of starting adjuvant ET with CDK 4/6 inhibitor and if the individual is no longer a candidate for additional ET in the metastatic setting.
•Individuals may have received prior targeted therapies, including but not limited to phosphatidylinositol 3\kinase (PI3K) inhibitors (for those with PIK3CA mutations) or mammalian target of rapamycin (mTOR) inhibitors. However, individuals can no longer be candidates for additional endocrine treatment with or without targeted therapies.
•Individuals with HIV must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease.
•Demonstrates adequate organ function.
•Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

排除标准

•Progressive disease within 6 months of completing (neo) adjuvant chemotherapy.
•Locally advanced metastatic breast cancer (mBC) (Stage IIIc) in individuals who are candidates for curative intent therapy at the time of study enrollment.
•Current enrollment in another clinical study or use of any investigational device or drug either within 5 half-lives or 28 days prior to randomization, whichever is longer.
•Received any prior treatment (including antibody-drug conjugate (ADC)) containing a chemotherapeutic agent targeting topoisomerase I.
•Received any prior treatment with a trophoblast cell-surface antigen 2 (Trop-2)-directed ADC.
•Have an active second malignancy.
•Have an active serious infection requiring antibiotics.
•Have active hepatitis B virus (HBV) or hepatitis C virus (HCV).
•Individuals positive for human immunodeficiency virus type 1/2 (HIV-1 or -2) with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
•Have a positive serum pregnancy test or are breastfeeding for individuals who are assigned female at birth.
•Note: Other protocol defined Inclusion/Exclusion criteria may apply.

研究者

发起方

Iwahori Yuki

相似试验

招募中

1 期

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer.Programmed cell death ligand 1 (PD-L1) negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting.MedDRA version: 27.0Level: LLTClassification code 10084066Term: Triple negative breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-005743-79-PLGilead Sciences, Inc.540

招募中

3 期

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast CancerTriple Negative Breast Cancer / PD-L1 Negative

JPRN-jRCT2041220122Iwahori Yuki540

招募中

1 期

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician'sChoice in Patients With Previously Untreated Locally Advanced Inoperableor Metastatic Triple-Negative Breast CancerProgrammed cell death ligand 1 (PD-L1) negative metastatic triple-negative breast cancer or PD-L1-positive metastatic triple-negative breast cancer previously treated with an anti-PD-(L)1 agent in the curative setting.MedDRA version: 27.0Level: LLTClassification code 10084066Term: Triple negative breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-005743-79-ATGilead Sciences, Inc.540

招募中

1 期

Study of Sacituzumab Govitecan-hziy plus Pembrolizumab Versus Treatment of Physician's Choice Plus Pembrolizumab in Participants with Previously Untreated, Locally Advanced, Inoperable (cannot be removed surgically), or Metastatic (spread to other locations in the body) Triple Negative Breast Cancer (breast cancer that does not have receptors for Oestrogen and progesterone hormones or HER2 proteins) that express PD-L1 biomarker (a type of protein found on cancer cells).Programmed cell death ligand 1 (PD-L1) positive metastatic triplenegative breast cancerMedDRA version: 23.0Level: LLTClassification code 10084066Term: Triple negative breast cancer metastaticSystem Organ Class: 100000004864

EUCTR2021-005742-14-ITGILEAD SCIENCES INCORPORATED440

招募中

1 期

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerProgrammed cell death ligand 1 (PD-L1) positive metastatic triple-negative breast cancerMedDRA version: 27.0Level: LLTClassification code 10084066Term: Triple negative breast cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2021-005742-14-PLGilead Sciences, Inc.440